Arbutus Biopharma (ABUS) Non-Current Assets (2010 - 2026)

Arbutus Biopharma (ABUS) has reported Non-Current Assets for 17 consecutive years, with $153000.0 the latest figure, recorded in Q1 2026.

• Quarterly Non-Current Assets fell 24.26% year-over-year to $153000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $731000.0 (down 96.96% YoY) and the FY2025 annual result came in at $162000.0, down 96.31% from the prior year.
• Non-Current Assets fell to $153000.0 in Q1 2026 per ABUS's latest filing, from $162000.0 in the prior quarter.
• Over the last five years, Non-Current Assets for ABUS reached as high as $64.2 million in Q1 2022 and fell as low as $148000.0 in Q2 2025.
• A 5-year average of $20.8 million and a median of $12.4 million in 2023 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets surged 621.19% — and 2025, when it sank 98.75%.
• Year by year, Non-Current Assets stood at $44.3 million in 2022, then plunged by 72.06% to $12.4 million in 2023, then tumbled by 64.51% to $4.4 million in 2024, then plunged by 96.31% to $162000.0 in 2025, then retreated by 5.56% to $153000.0 in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $153000.0, $162000.0, and $268000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.